"FGF21 Mutants and Uses Thereof" in Patent Application Approval Process (USPTO 20240076333).

This patent application discusses the invention of nucleic acid molecules encoding FGF21 mutant polypeptides, which have potential applications in treating metabolic disorders such as diabetes and obesity. The application describes various amino acid substitutions in the FGF21 polypeptide sequence that can enhance its half-life and therapeutic efficacy. It also mentions the possibility of linking the polypeptides to polymers or fusing them with other amino acid sequences. Pharmaceutical compositions containing these FGF21 mutant polypeptides are proposed for the treatment of metabolic disorders. The application includes detailed information on the amino acid sequences, nucleic acid molecules, and vectors encoding the polypeptide. [Extracted from the article]

Copyright of Drug Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)